MAD2L2 and ovarian carcinoma: BRCA1-mutated, HR-deficient breast or ovarian cancer cells are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors, and resistance to PARP inhibitors in BRCA1-mutated cells is induced by restoration of HR, which is triggered by REV7 depletion [62].